A Single-Center, Open-Label Study Investigating the Excretion Balance, Pharmacokinetics, Metabolism, and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 20 Dec 2017
At a glance
- Drugs Idasanutlin (Primary) ; Idasanutlin (Primary)
- Indications Cancer
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Roche
- 04 Jul 2017 Status changed from active, no longer recruiting to completed.
- 10 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Nov 2016 Planned End Date changed from 1 Oct 2017 to 1 Nov 2017.